Tabitha Reed and Julia Cockroft examine the Tribunal’s ruling, its implications for suppliers of branded medicines, and ...

Cognizant (Nasdaq: CTSH) and Boehringer Ingelheim announced today the go-live of an end-to-end technology platform powered by ...

Boehringer Ingelheim and Veeva Systems (NYSE: VEEV) have announced the launch of Boehringer’s One Medicine Platform, powered by the successful implementation of Veeva Development Cloud. They first ...

The One Medicine Platform replaces 20+ legacy platforms—unifying medicinal development processes & data sources into a ...

Privately-held Swedish firm Salipro Biotech AB, a specialist in the stabilization of challenging drug targets, today ...

Boehringer Ingelheim will conduct biophysical and structural studies ... We are not an agent for these third parties nor do we endorse or guarantee their products. We make no representation or ...

Germany’s Boehringer Ingelheim has launched the One Medicine Platform, a new system designed to streamline drug development, ...

Learn more at https://www.boehringer-ingelheim.com. About Veeva Systems Veeva is the global ... Statements This release contains forward-looking statements regarding Veeva's products and services and ...

"With this new system, Boehringer Ingelheim is expected to resolve data challenges and latencies and speed up the go-to-market of its products. Thanks to the close collaboration across our teams ...

parasite-control products, and medicines for pets, horses, and livestock to veterinarians, animal owners, farmers, and governments. As a leader in animal health, Boehringer Ingelheim values that ...

Generic versions of diabetes drug Empagliflozin launched in India, crashing prices by 80-90% on day one post-patent expiry.

New Delhi: In response to the proposal presented by Boehringer Ingelheim, the Subject Expert Committee (SEC) functional under ...